GFAP and Alzheimer disease: We found higher levels of both plasma GFAP and NfL to be broadly associated with worse outcomes for most baseline cognitive domains, for cognitive decline, and for loss of functional independence in the pooled cohort of all diseases, which appeared to be driven mostly by the AD/MCI and PD cohorts in which similar associations were found.